A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

NCT03206073 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

Colorectal Cancer
Colorectal Carcinoma
Colorectal Adenocarcinoma
Refractory Cancer
Colorectal Neoplasms

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
BIOLOGICAL: Pexa-Vec
BIOLOGICAL: Pexa-Vec

Sponsor

National Cancer Institute (NCI)